EnGeneIC Pty Ltd
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From EnGeneIC Pty Ltd
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- EnGeneIC Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.